Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

Compounded Tirzepatide vs Zepbound: The Differences Explained

Compounded tirzepatide vs Zepbound comes down to who checked the drug. Zepbound is Eli Lilly's tirzepatide, and it won FDA approval in November 2023 after two trials. Compounded tirzepatide is mixed by a compounder, has no FDA approval, and gets no FDA review before it is sold.

This page puts the two side by side: who makes each one, what FDA approval looks at, what FDA has reported going wrong, and the rules as of 15 November 2026. For what compounded tirzepatide is and its full history, see our compounded tirzepatide glossary entry.

On this page

Key facts

Approval: Zepbound has it, for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Compounded tirzepatide has none.

Checks before sale: Zepbound won FDA approval after two trials, and its label lists its formulation. FDA does not review a compounded drug for safety, effectiveness or quality before sale.

The molecule: no FDA source we read says the compounded version is identical to Zepbound, and none says it differs.

FDA reports: over 730 reports of health problems after compounded tirzepatide by 31 May 2026. FDA says adverse events are likely underreported.

Rules on 15 November 2026: the shortage is over, copies are tightly limited, and the plan to leave tirzepatide off the 503B bulks list is still a proposal.

Sources: FDA news release on Zepbound, 8 November 2023; FDA compounding questions and answers; FDA page listing its worries about unapproved GLP-1 weight drugs; FDA dated updates on GLP-1 compounding policy; Federal Register, 503B bulks list notice, 26 June 2026

How is compounded tirzepatide different from Zepbound?

Zepbound's active ingredient, tirzepatide, switches on the receptors for two gut hormones, GLP-1 and GIP. FDA has not said whether a compounded product is identical to that molecule or different, and it says marketers must not claim the same active ingredient. What the sources do show is who makes each one, who checks it, and what proof stands behind it.

Zepbound against compounded tirzepatide, from FDA pages, the Zepbound label and an August 2026 court opinion, checked 15 November 2026.
PointZepboundCompounded tirzepatide
Who makes itEli LillyA compounder: a state-licensed pharmacy (503A) or an outsourcing facility (503B)
FDA approvalYes. It won FDA approval in November 2023 to help manage weight long termNo
FDA review before saleWon FDA approval after two trials, and its label lists its formulationNone. FDA does not review its safety, effectiveness or quality before it is sold
Trials behind itTwo randomized, placebo-controlled trials that measured weight loss at 72 weeksNo FDA check of its safety, effectiveness or quality before it is sold
RecipeOne formulation listed on its label, sterile and preservative-freeNo FDA label listing it
ContainersPens and containers meant for one use eachMay come in containers meant for more than one use
Compounder oversightNot a compounded drugState pharmacy boards mainly for 503A pharmacies, which need not follow CGMP; FDA for 503B facilities, which must
Generic?It is the brandNo. FDA says compounded drugs are not generics

Lilly sells its tirzepatide under a second brand, Mounjaro, for blood sugar in adults with type 2 diabetes. Our guide on whether Zepbound is the same as Mounjaro covers that split, and our animated tirzepatide explainer shows how the molecule works on both receptors.

Sources: FDA news release on Zepbound, 8 November 2023; Zepbound label, revised December 2024; FDA compounding questions and answers; Fifth Circuit opinion, 27 August 2026; FDA page listing its worries about unapproved GLP-1 weight drugs

What does FDA approval check that compounding skips?

Zepbound won FDA approval on the strength of two trials, and its label lists one formulation. FDA does not review a compounded drug for safety, effectiveness or quality before it is sold.

The trials. The weight approval for Zepbound rested on two randomized, double-blind trials, each with a placebo group. They measured weight loss after 72 weeks, with 2,519 people on Zepbound and 958 on placebo across both. A second approval, in December 2024, covers adults with obesity who have moderate to severe obstructive sleep apnea. FDA called it the first drug option for some people with that condition. Our guide on Zepbound and sleep apnea covers that use.

The recipe. The Zepbound label lists one formula: tirzepatide, sodium chloride, a sodium phosphate salt and sterile water, with hydrochloric acid or sodium hydroxide possibly added to adjust the pH. It is sterile and has no preservative. It comes in pens and other containers meant for one use each.

The compounded side. Before a compounded drug reaches patients, FDA checks none of its safety, effectiveness or quality. FDA also warns that careless compounding can mean a contaminated product, or the wrong amount of the active ingredient.

Sources: FDA news release on Zepbound, 8 November 2023; FDA news release on sleep apnea, 20 December 2024; Zepbound label, revised December 2024; FDA compounding questions and answers

Who makes each one, and who checks them?

Zepbound has one maker, Eli Lilly. Compounded tirzepatide can come from two kinds of compounder, and each kind answers to a different watchdog.

  • Eli Lilly: per an August 2026 appeals court opinion, Mounjaro and Zepbound are the only tirzepatide products with FDA approval. The court said Lilly holds the sole right to make tirzepatide products until 2027, under a five-year rule for new active ingredients. That is not a patent date, and it does not say when other versions will arrive.

The two kinds are 503A pharmacies and 503B outsourcing facilities. Our glossary entry explains who oversees each in the 503A and 503B split.

Sources: Fifth Circuit opinion, 27 August 2026; FDA compounding questions and answers; FDA dated updates on GLP-1 compounding policy

Is compounded tirzepatide the same molecule as Zepbound?

Nobody can say from FDA sources. FDA says marketers must not claim a compounded drug is the same as an approved one. And no FDA statement we found compares the compounded molecule with Zepbound, either to call it identical or to call it different.

What FDA does publish is the Zepbound molecule itself. Its label spells out the structure: a chain built on the GIP hormone, with a 20-carbon fatty tail that grips albumin, a blood protein, so the drug lasts longer. For compounded GLP-1 drugs that are mass-marketed as similar alternatives to approved drugs, FDA says it cannot verify quality, safety or efficacy. That gap, not a known change in the molecule, is the difference the FDA sources support.

Claims about compounded tirzepatide, and what the FDA pages we read on 15 November 2026 say.
ClaimWhat the FDA sources say
Compounded tirzepatide is the exact same molecule as ZepboundNo FDA page we read says it is, or that it is not. FDA says it cannot verify the quality, safety or efficacy of compounded GLP-1 drugs that are mass-marketed as similar alternatives to approved drugs.
It is a generic version of ZepboundNo. FDA says compounded drugs are not generics, and generics are drugs FDA does approve.
It comes from an FDA-licensed pharmacyFDA tells marketers not to say this, because FDA does not approve or license any facility.
FDA warned about tirzepatide salt formsNo. The FDA salt-form warning, and its vitamin B12 add-on example, name semaglutide, a different drug.
Compounding tirzepatide is now bannedThe FDA pages we read describe no blanket ban. Copies are tightly limited, and the bulks list exclusion was still a proposal on 15 November 2026.

How FDA polices the wording. In February 2026, FDA said marketers cannot call compounded drugs generic versions of approved drugs, or the same as them. They also cannot claim the compounded drug uses the same active ingredient. In March 2026, FDA sent 30 warning letters to telehealth companies. The main problems were implying sameness with approved drugs and hiding who really made the product.

Sources: Zepbound label, revised December 2024; FDA statement, 6 February 2026; FDA release on 30 telehealth warning letters, 3 March 2026; FDA page for telehealth companies on compounded drugs; FDA compounding questions and answers; FDA page listing its worries about unapproved GLP-1 weight drugs; FDA dated updates on GLP-1 compounding policy

What problems has FDA reported with compounded tirzepatide?

FDA keeps a count of adverse event reports, meaning health problems reported after someone used a drug. As of 31 May 2026, it had more than 730 tied to compounded tirzepatide. FDA cannot always tell whether the drug caused the problem. FDA says adverse events are likely underreported, since federal law does not make 503A pharmacies report these events to FDA. Many of the reports looked like known side effects of the approved drugs.

  • Fake labels: FDA knows of falsely labeled compounded tirzepatide. Some labels name pharmacies that do not exist. Others name real, licensed pharmacies that never made the product.
  • Handling: compounded GLP-1 drugs may come in containers meant for more than one use. FDA says those carry a higher contamination risk after 28 days from first use. It has also had complaints of shipments arriving warm or with too few ice packs.
  • A warning letter: in April 2026, FDA wrote to an outsourcing facility that had compounded tirzepatide from bulk ingredient, which did not qualify for 503B exemptions. The same facility had recalled a lot of compounded tirzepatide in October 2025 because its sterility could not be assured.
  • Imported ingredients: FDA set up a green list import alert, 66-80, to stop GLP-1 bulk ingredients with possible quality problems from entering the US. Ingredients from makers that appear to meet FDA standards are not affected.

One warning needs a careful read. FDA cautions about salt forms and vitamin B12 add-ons, but those warnings name semaglutide, a different drug. We found no FDA page naming a salt-form problem with tirzepatide. For side effects of the approved drugs, see our GLP-1 side effects guide.

Sources: FDA page listing its worries about unapproved GLP-1 weight drugs; FDA warning letter to an outsourcing facility, 7 April 2026; FDA dated updates on GLP-1 compounding policy

Why could pharmacies copy Zepbound before, and what changed?

Because tirzepatide sat on the FDA shortage list from December 2022, and while a drug is listed, some federal limits on compounded copies stop applying. FDA ruled that shortage over on 19 December 2024, after a first ruling and a court remand. Grace periods for compounders ran out in March 2025, and the Fifth Circuit upheld the decision on 27 August 2026. Dates, wind-down rules and the court steps are in our glossary timeline.

Sources: FDA shortage decision memo, 19 December 2024; FDA page on compounding drugs in shortage; FDA dated updates on GLP-1 compounding policy; Fifth Circuit opinion, 27 August 2026

Is compounded tirzepatide still allowed?

Only in narrow cases. In its April 2026 update, still live on 15 November 2026, FDA said tirzepatide is on neither its shortage list nor the 503B bulks list. Outsourcing facilities need a substance on that bulks list to compound from bulk under 503B.

Limits on pharmacy copies. FDA limits pharmacy-made copies of an approved drug, and our compounded tirzepatide glossary entry sets out how FDA defines a copy.

What is still pending. On 30 April 2026, FDA proposed excluding tirzepatide from the 503B bulks list, along with semaglutide and liraglutide. In its view, outsourcing facilities have no clinical need to make it from bulk. Comments were due by 30 July 2026, and no final decision had been published by 15 November 2026.

FDA's stated view is that a compounded drug belongs only where an approved drug cannot meet a patient's needs. That is FDA's view, not advice from us. Which treatment fits one person is a question for their licensed clinician. Under our medical review policy, each status fact here was checked against the cited records on 15 November 2026.

Sources: FDA dated updates on GLP-1 compounding policy; FDA warning letter to an outsourcing facility, 7 April 2026; Federal Register, 503B bulks list notice, 26 June 2026; FDA page listing its worries about unapproved GLP-1 weight drugs

What else do people ask about compounded tirzepatide vs Zepbound?

What is the main difference between compounded tirzepatide and Zepbound?+

Zepbound won FDA approval in November 2023 after two trials, and its label lists its formulation. Compounded tirzepatide has no FDA approval, and FDA does not review its safety, effectiveness or quality before it is sold.

Is compounded tirzepatide the same as Zepbound?+

No FDA source we read says the compounded molecule is identical to Zepbound, and none says it is different. FDA says it cannot verify the quality, safety or efficacy of compounded GLP-1 drugs that are mass-marketed as similar alternatives to approved drugs. It also says marketers may not call compounded products the same as an approved drug.

Does compounded tirzepatide have FDA approval?+

No. As of 15 November 2026, compounded tirzepatide has no FDA approval. A federal appeals court opinion from August 2026 names Mounjaro and Zepbound as the only tirzepatide products with FDA approval.

Is compounded tirzepatide a generic?+

No. FDA says compounded drugs are not generics. A generic goes through FDA review and approval. A compounded drug does not.

Is compounded tirzepatide still legal?+

It is tightly limited. Tirzepatide is on neither the FDA shortage list nor the 503B bulks list, so outsourcing facilities cannot compound it from bulk under the 503B exemptions. For now, FDA says it does not intend to act against a 503A pharmacy filling four or fewer prescriptions a month for an essentially-a-copy product.

Why were pharmacies allowed to copy Zepbound before?+

Tirzepatide was on the FDA shortage list from December 2022. While a drug is listed, some federal limits on compounded copies stop applying. FDA ruled the shortage over in December 2024, the grace periods ended in March 2025, and an appeals court upheld the decision in August 2026.

How many problems has FDA logged with compounded tirzepatide?+

As of 31 May 2026, FDA had logged over 730 adverse event reports linked to compounded tirzepatide. A report does not prove the drug caused the problem. FDA also says adverse events are likely underreported, because federal law does not make 503A pharmacies, the ones that are not outsourcing facilities, send these reports to FDA.

What did FDA propose about tirzepatide in 2026?+

On 30 April 2026, FDA proposed excluding tirzepatide from the 503B bulks list, since it saw no clinical need for 503B facilities to make it from bulk. Comments were due by 30 July 2026. A search on 15 November 2026 found no final decision.

What is Zepbound approved for?+

In the US, Zepbound is approved to help manage weight over the long term in adults living with obesity, or carrying extra weight with a health problem linked to it, along with diet and exercise. Since December 2024 it is also approved for adults with obesity who have moderate to severe obstructive sleep apnea.

Sources: FDA news release on Zepbound, 8 November 2023; FDA news release on sleep apnea, 20 December 2024; FDA compounding questions and answers; FDA statement, 6 February 2026; Fifth Circuit opinion, 27 August 2026; FDA dated updates on GLP-1 compounding policy; FDA shortage decision memo, 19 December 2024; FDA page listing its worries about unapproved GLP-1 weight drugs; Federal Register, 503B bulks list notice, 26 June 2026

So what is actually different?

Zepbound won FDA approval after two trials, and its label lists its formulation. FDA does not review compounded tirzepatide for safety, effectiveness or quality before sale, and no FDA source settles whether its molecule matches. The shortage exception that once lifted some limits on copies is over, and the copies allowed today are tightly limited.

Molecule Mechanics is a YouTube channel of short animated explainers, each with its sources listed underneath. Everything above reflects the FDA pages, the Zepbound label and the August 2026 court opinion as we read them on 15 November 2026. The episode voice is AI-generated with ElevenLabs, over drawings made for the series. Our semaglutide vs tirzepatide comparison sets those two weight drugs side by side, and our guide on how long people stay on Zepbound covers the long-term research.

Spotted a fact that looks off? Our corrections policy explains how to flag it.

Browse every Molecule Mechanics upload on YouTube

Sources: FDA news release on Zepbound, 8 November 2023; Molecule Mechanics channel

This guide explains rules and records for learning. It is not medical advice and does not steer anyone toward a treatment. Its facts come from FDA pages and records, the Zepbound label and a federal court opinion, cited section by section. Treatment decisions sit with a licensed clinician.

Sources

  1. 1.FDA news release dated 8 November 2023: Zepbound (tirzepatide) won approval for long-term (chronic) weight management, for adults living with obesity, or carrying extra weight with a weight-linked health problem, alongside eating fewer calories and moving more; it rested on two randomized, double-blind, placebo-controlled trials that measured weight loss after 72 weeks (2,519 people on Zepbound and 958 on placebo in total); it activates the receptors of two gut hormones, GLP-1 and GIP; tirzepatide was already approved as Mounjaro for blood sugar in type 2 diabetes.
  2. 2.FDA news release dated 20 December 2024: a second Zepbound approval, for adults with obesity who have moderate to severe obstructive sleep apnea; FDA called it the first drug option for some of these patients.
  3. 3.Zepbound prescribing information, revised December 2024, sections 11 and 12.1: the exact tirzepatide structure, built on the GIP sequence with a C20 fatty diacid that binds albumin and prolongs the half-life; the listed inactive ingredients; a sterile, preservative-free solution in single-use pens or containers.
  4. 4.US Court of Appeals for the Fifth Circuit, opinion filed 27 August 2026, not designated for publication: affirmed the district court and upheld the FDA tirzepatide shortage decision; Mounjaro (May 2022) and Zepbound (November 2023) are the only tirzepatide products with FDA approval; Lilly holds an exclusive right to make tirzepatide products until 2027 under the five-year new active ingredient rule.
  5. 5.FDA decision memo dated 19 December 2024: tirzepatide shots joined the shortage list on 15 December 2022; Zepbound pens were added in April 2024 for high demand, and Zepbound in single-use containers other than pens never was; the court remand of 11 October 2024; supply met demand nationally, and local gaps most likely sat between Lilly and individual customers; outsourcing facilities give more assurance of quality.
  6. 6.FDA page of dated updates on compounding policy as GLP-1 supply steadied, entries from 2 October 2024 to 1 April 2026, read 15 November 2026: shortage resolved on 2 October 2024 and again on 19 December 2024; the 60 and 90 day wind-downs; the 5 March 2025 injunction denial; tirzepatide missing from both the 503B bulks list and the shortage list; the essentially a copy test and the four or fewer prescriptions policy; the vitamin B12 example, which names semaglutide.
  7. 7.FDA page on compounding when drugs are on the shortage list, current as of 8 August 2025: some federal limits on copies stop applying while a drug is listed, but other conditions and requirements remain.
  8. 8.FDA compounding questions and answers, current as of 16 September 2025: compounded drugs do not have FDA approval and are not generics; sloppy compounding can lead to contamination or the wrong amount of active ingredient; outsourcing facilities (created in 2013) are inspected on a risk-based schedule and must follow CGMP; state boards mainly oversee 503A pharmacies.
  9. 9.Federal Register notice of 26 June 2026: comment period on the proposal to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list extended to 30 July 2026. The proposal itself is dated 30 April 2026 (notice 2026-08552, 1 May 2026). A Federal Register search on 15 November 2026 found no final decision.
  10. 10.FDA statement dated 6 February 2026: FDA intends to restrict GLP-1 ingredients meant for non-approved compounded drugs that are mass-marketed as similar alternatives, because it cannot verify their quality, safety or efficacy; marketers cannot call them generic versions of, or the same as, approved drugs, or say they use the same active ingredient.
  11. 11.FDA release dated 3 March 2026: FDA sent 30 telehealth firms warning letters about untrue or misleading marketing of compounded GLP-1 drugs, mainly implied sameness with approved drugs and hidden sourcing.
  12. 12.FDA page setting out its worries about unapproved GLP-1 weight loss drugs, current as of 1 October 2026, read 15 November 2026: over 730 adverse event reports linked with compounded tirzepatide by 31 May 2026; likely underreporting; fake labels; contamination risk in containers meant for more than one use after 28 days from first use; shipments arriving warm; the green list import alert 66-80; salt-form warnings that name semaglutide only; compounded drugs should only be used when an approved drug cannot meet a patient need.
  13. 13.FDA warning letter to an outsourcing facility, 7 April 2026: tirzepatide is not on the 503B bulks list or the shortage list, so compounding it from bulk did not qualify; the facility recalled a lot of compounded tirzepatide in October 2025 for lack of sterility assurance.
  14. 14.FDA page for telehealth companies on promoting compounded drugs, current as of 15 June 2026: FDA does not approve or license any facility.